ATE413192T1 - Die vorbeugung und behandlung von netzhautischämie und ödem - Google Patents

Die vorbeugung und behandlung von netzhautischämie und ödem

Info

Publication number
ATE413192T1
ATE413192T1 AT99967762T AT99967762T ATE413192T1 AT E413192 T1 ATE413192 T1 AT E413192T1 AT 99967762 T AT99967762 T AT 99967762T AT 99967762 T AT99967762 T AT 99967762T AT E413192 T1 ATE413192 T1 AT E413192T1
Authority
AT
Austria
Prior art keywords
antagonist
edema
prevention
treatment
retinal ischemia
Prior art date
Application number
AT99967762T
Other languages
English (en)
Inventor
Anthony Adamis
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE413192T1 publication Critical patent/ATE413192T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Computer And Data Communications (AREA)
AT99967762T 1998-12-30 1999-12-29 Die vorbeugung und behandlung von netzhautischämie und ödem ATE413192T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11422198P 1998-12-30 1998-12-30
US09/248,752 US6670321B1 (en) 1998-12-30 1999-02-12 Prevention and treatment for retinal ischemia and edema

Publications (1)

Publication Number Publication Date
ATE413192T1 true ATE413192T1 (de) 2008-11-15

Family

ID=26811943

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99967762T ATE413192T1 (de) 1998-12-30 1999-12-29 Die vorbeugung und behandlung von netzhautischämie und ödem

Country Status (7)

Country Link
US (5) US6670321B1 (de)
EP (1) EP1140172B1 (de)
AT (1) ATE413192T1 (de)
AU (1) AU761646B2 (de)
CA (1) CA2357873A1 (de)
DE (1) DE69939878D1 (de)
WO (1) WO2000038714A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155511A1 (en) * 2000-09-08 2002-10-24 Carolyn Horrocks Novel antibody compositions for the negative selection of specific rat leukocyte subsets
WO2002034283A2 (en) * 2000-10-27 2002-05-02 Novartis Ag Vegh inhibitors and their use
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
ATE464321T1 (de) * 2002-08-28 2010-04-15 Novartis Pharma Gmbh Gentherapie des auges
JP5105578B2 (ja) * 2003-11-05 2012-12-26 サーコード バイオサイエンス インコーポレイテッド 細胞接着のモジュレーター
US7731360B2 (en) * 2003-11-07 2010-06-08 Neuro Kinetics Portable video oculography system
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US20080299130A1 (en) * 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
US8168655B2 (en) 2005-05-17 2012-05-01 Sarcode Bioscience Inc. Compositions and methods for treatment of eye disorders
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
EP1984501B1 (de) 2006-02-14 2011-05-18 Noxxon Pharma AG Mcp-i-bindende nukleinsäuren
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US8197435B2 (en) * 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
WO2007131050A2 (en) * 2006-05-02 2007-11-15 Georgia Tech Research Corporation Method for drug delivery to ocular tissue using microneedle
RU2313312C1 (ru) * 2006-05-03 2007-12-27 Федеральное государственное учреждение "МОСКОВСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ имени ГЕЛЬМГОЛЬЦА ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ моделирования ишемии сетчатки глаза
US7803148B2 (en) 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
EP2056793A4 (de) * 2006-07-31 2011-08-17 Neurosystec Corp Nanopartikel mit freier base aus gacyclidine
US7553486B2 (en) * 2006-11-13 2009-06-30 Paul Theodore Finger Anti-VEGF treatment for radiation-induced vasculopathy
WO2008103301A2 (en) * 2007-02-16 2008-08-28 President And Fellows Of Harvard College Treatment of the eye using macrophages and/or agents able to affect blood vessel morphology
WO2008136772A1 (en) * 2007-05-02 2008-11-13 Agency For Science, Technology And Research Method of monitoring retinopathy
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
US20090170770A1 (en) * 2007-11-06 2009-07-02 Ali Hafezi-Moghadam Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap 1) inhibitor
WO2009068318A1 (en) * 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-i binding nucleic acids and use thereof
US9655515B2 (en) * 2008-04-08 2017-05-23 Neuro Kinetics Method of precision eye-tracking through use of iris edge based landmarks in eye geometry
EP2265124A4 (de) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc Aerosolisierte lfa-1-antagonisten zur verwendung bei der lokalen behandlung von immunerkrankungen
JP2011516607A (ja) * 2008-04-15 2011-05-26 サーコード コーポレイション 胃腸系へのｌｆａ−１アンタゴニストの送達
WO2009139817A2 (en) 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
ES2763703T3 (es) 2008-04-15 2020-05-29 Sarcode Bioscience Inc Antagonistas de LFA-1 tópicos utilizados en el tratamiento localizado de trastornos inmunes
US8585609B2 (en) * 2008-10-09 2013-11-19 Neuro Kinetics, Inc. Quantitative, non-invasive, clinical diagnosis of traumatic brain injury using simulated distance visual stimulus device for neurologic testing
US10398309B2 (en) 2008-10-09 2019-09-03 Neuro Kinetics, Inc. Noninvasive rapid screening of mild traumatic brain injury using combination of subject's objective oculomotor, vestibular and reaction time analytic variables
US9039631B2 (en) 2008-10-09 2015-05-26 Neuro Kinetics Quantitative, non-invasive, clinical diagnosis of traumatic brain injury using VOG device for neurologic testing
WO2010048365A2 (en) * 2008-10-23 2010-04-29 Arizona Technology Enterprises Therapeutic peptide bioconjugates
WO2010054393A1 (en) * 2008-11-10 2010-05-14 Mount Sinai School Of Medicine Of New York University Methods of inhibiting inflammation-associated tissue damage by inhibiting neutrophil activity
EP2425241A4 (de) * 2009-04-27 2015-05-13 Abbott Lab Verfahren zur unterscheidung roter blutzellen von weissen blutzellen durch vorwärtsstreuung aus einem laser in einem automatisierten hämatologischen analysegerät
US8389474B1 (en) * 2009-07-14 2013-03-05 Alan Anson Wanderer Rationale for IL-1 β targeted therapy to improve harvested organ viability, allograft tolerance, replant success and for conditions characterized by reduced or absent arterial perfusion
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
WO2011065968A1 (en) * 2009-11-30 2011-06-03 The Scripps Research Institute Use of monocyte chemoattractant compounds to treat ocular disorders
EP2627292B1 (de) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Vorrichtung für okularen zugang
US9705124B2 (en) 2012-02-27 2017-07-11 The Johns Hopkins University High energy density Li-ion battery electrode materials and cells
SI3715345T1 (sl) 2012-07-25 2024-07-31 Bausch + Lomb Ireland Limited Priprava zaviralca lfa-1
US8808179B1 (en) 2012-08-06 2014-08-19 James Z. Cinberg Method and associated apparatus for detecting minor traumatic brain injury
EP2887982B1 (de) 2012-08-27 2022-11-23 Clearside Biomedical, Inc. Vorrichtung zur arzneimittelverabreichung mit mikronadeln
KR102467714B1 (ko) 2012-11-08 2022-11-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
AU2014259694B2 (en) 2013-05-03 2018-11-08 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US20160310417A1 (en) 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
WO2015196085A2 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
EP3394100B1 (de) * 2015-12-23 2025-07-16 Sorbonne Université Mittel zur hemmung der bindung von cfh an cd11b/cd18 und verwendungen davon
WO2017139375A1 (en) 2016-02-10 2017-08-17 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
EP3458612B1 (de) 2016-05-17 2023-11-15 Genecentric Therapeutics, Inc. Verfahren zur subtypisierung von lungenadenokarzinomen
CN109863251B (zh) 2016-05-17 2022-11-18 基因中心治疗公司 对肺鳞状细胞癌亚型分型的方法
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
US12090294B2 (en) 2017-05-02 2024-09-17 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
EP3665199A4 (de) 2017-08-07 2021-08-11 Genecentric Therapeutics, Inc. Verfahren zur subtypisierung von plattenepithelkarzinomen an kopf und hals
CA3115922A1 (en) 2018-10-09 2020-04-16 Genecentric Therapeutics, Inc. Detecting cancer cell of origin
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
EP4093508A1 (de) 2020-01-24 2022-11-30 Pfizer Inc. Anti-e-selectin-antikörper, zusammensetzungen und verwendungsverfahren
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
EP0314863B1 (de) 1987-11-02 1994-12-07 Baylor College Of Medicine Verwendung von ICAM-1 oder ihre funktionelle Derivate zur Behandlung unspezifischer Entzündungen
CA2008368C (en) 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
GB9009549D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Recombinant antibody and method
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5223396A (en) 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
AU667487B2 (en) 1991-10-01 1996-03-28 General Hospital Corporation, The Preventing allograft rejection with antibodies to adhesion molecules
JP3679112B2 (ja) 1991-10-04 2005-08-03 アメリカ合衆国 細胞接着分子の遮断による眼の炎症の治療
US5831029A (en) * 1993-12-23 1998-11-03 Icos Corporation Human β2 integrin α subunit
JPH08332181A (ja) * 1995-06-09 1996-12-17 Kdk Corp 生体の位置決め方法および生体情報測定用位置決め装置並びに生体情報測定装置
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
CA2256456A1 (en) * 1996-05-30 1997-12-11 The University Of British Columbia Enhanced efficacy of liposomal antisense delivery
US5814500A (en) 1996-10-31 1998-09-29 The Johns Hopkins University School Of Medicine Delivery construct for antisense nucleic acids and methods of use
WO1998024797A1 (en) 1996-12-02 1998-06-11 Dyad Pharmaceutical Corporation Antisense inhibition of human adhesion molecules
JP2001521520A (ja) 1997-04-11 2001-11-06 ジー．ディー．サール アンド カンパニー 抗α▲下ｖ▼β▲下３▼インテグリン抗体アンタゴニスト
EP1061913B1 (de) 1998-03-13 2007-06-27 The Johns Hopkins University School Of Medicine Verwendung von einem protein kinase hemmer wie z.b. genistein bei der behandlung von diabetischer retinopathie
ATE330631T1 (de) * 1999-01-05 2006-07-15 Univ Southern Australia Antikörperfragmente zur lokalen behandlung von augenerkrankungen

Also Published As

Publication number Publication date
US6524581B1 (en) 2003-02-25
EP1140172A1 (de) 2001-10-10
DE69939878D1 (de) 2008-12-18
CA2357873A1 (en) 2000-07-06
EP1140172B1 (de) 2008-11-05
AU2398500A (en) 2000-07-31
US20080019977A1 (en) 2008-01-24
US20040028648A1 (en) 2004-02-12
US6670321B1 (en) 2003-12-30
US20100203061A1 (en) 2010-08-12
WO2000038714A1 (en) 2000-07-06
WO2000038714A8 (en) 2000-08-03
AU761646B2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
DE69939878D1 (de) Die vorbeugung und behandlung von netzhautischämie und ödem
DK0703786T3 (da) Anvendelse af nona- og dekapeptider til fremstilling af et lægemiddel til behandling af AIDS
IL144643A0 (en) Jak-3 inhibitors for treating allergic disorders
NO20035743D0 (no) Substituerte oksazolindinoner for kombinasjonsterapi
PL366579A1 (en) Treatment of nail infections with no
AU5338301A (en) Methods and compositions for modulating alpha adrenergic receptor activity
HRP20020593B1 (hr) Liječenje ozljeda mozga, kralježnične moždine i živca
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
DE69814049D1 (de) Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
EP2082749A3 (de) Vorbeugung und Behandlung für Morbus Alzheimer
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
DK0946157T3 (da) Topisk anvendelse af kappa-opioid agonister til behandling af øjensmerte
ATE261737T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und ein herzglykosid enthalten
EA199900843A1 (ru) Синтез 1,3-оксаселеноланнуклеозидов, их активность против вируса иммунодефицита человека и против вируса гепатита-b
ID24184A (id) Obat untuk perawatan disfungsi ereksi
BR0111267A (pt) Cicloexilaminas bicìclicas e seu uso como antagonistas do receptor de nmda
DE60026491D1 (de) Melagatran zur behandlung von entzündungen
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
ATE429216T1 (de) Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson
DE60221104D1 (de) Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose
ATE306275T1 (de) Pharmazeutische zubereitungen zur behandlung von dns viraler infektionen, welche ein schleifendiureticum und lithium enthalten
ATE373475T1 (de) Carbamate von 2-heterozyklischen 1,2-ethandiolen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties